Observational studyMedicine2017
Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments.Clinical and experimental medicine · 2025Review
- Health-Related Quality of Life in Patients with Chronic Hepatitis B: A Meta-Analysis of Observational Studies.Iranian journal of public health · 2023Review
- Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method.Frontiers in pharmacology · 2021Article
- Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma.The Journal of international medical research · 2020Article
- Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma.Infectious agents and cancer · 2020Article
- Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma.Oncology letters · 2019Article
- [Alanine aminotransferase normalization with antiviral therapies in hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan.Experimental and therapeutic medicine · 2019Article
- Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study.Medicine · 2019Observational
- Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer.Medicine · 2019Observational
- Health related quality of life in stroke patients and risk factors associated with patients for return to work.Medicine · 2019Article
- Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy.Medicine · 2019Observational
- Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B.Infection and drug resistance · 2019Article
- Risk factors associated with fatigue in chronic hepatitis B patients.Patient preference and adherence · 2019Article
- Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy.Pharmacogenomics and personalized medicine · 2019Article
- Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.Infectious agents and cancer · 2019Article
- Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus.Medicine · 2018Article
- Observational
- Intraperitoneal hypertension, a novel risk factor for sepsis-associated encephalopathy in sepsis mice.Scientific reports · 2018Article
- Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome.United European gastroenterology journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization.Of 180 patients studied, 56 received de novo telbivudine monotherapy (LDT group); 45 received entecavir monotherapy (ETV group); 40 received LDT following interferon (interferon-telbivudine [IFN-LDT] group); and 39 received ETV following interferon (interferon-entecavir [IFN-ETV] group). At week 52, virological response occurred in significantly more patients in the IFN-ETV group than the ETV group (87.2% vs 57.8%, P = .003). At week 104, HBeAg seroconversion occurred in significantly more patients in the IFN-ETV group than the ETV group (44.4% vs 22.2%, P = .03). At week 52, virological response was achieved by significantly more patients in the IFN-LDT group than the LDT group (85.0% vs 64.3%, P = .02).This study showed that switch to rescue therapy with ETV or LDT therapy after failure of interferon therapy resulted in more rapid virologic response than with de novo treatment with either ETV or LDT; rescue therapy with ETV resulted in a greater HBeAg seroconversion rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.